Pfizer To Pay $6.7B In Cash For Arena Pharmaceuticals

FILE - The Pfizer logo is displayed at the company's headquarters in New York, on Feb. 5, 2021. In a statement on Tuesday, Nov. 16, 2021, drugmaker Pfizer Inc. said it has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental coronavirus pill, in a move that could make its treatment available to more than half of the world’s population. (AP Photo/Mark Lennihan, File)

Pfizer is spending $6.7 billion to buy a drugmaker with no products on the market and a focus on developing treatments for inflammatory conditions like Chrohn’s disease. The pharmaceutical giant said Monday it will pay $100 in cash for each share of Arena Pharmaceuticals in a deal already approved by the boards of both companies. Pfizer says the deal will help bolster its expertise in inflammation and immunology. It plans to pay for the acquisition with cash on hand. Arena has a potential treatment for ulcerative colitis in late-stage clinical testing that it also is testing to treat Chrohn’s disease.

Governor Newsom to Ask Legislature to Use Texas Abortion Strategy to Tackle Guns

Previous article

‘Y’all Pray For Mayfield’: Town Grieves In Tornado Aftermath

Next article

You may also like